Article
Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in mice
2022-12-21
Abstract excerpt
Obesity is rapidly increasing within the global population and is one of the leading causes of chronic diseases, including type 2 diabetes (T2D), non-alcoholic fatty liver disease, and cardiovascular diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as promising therapeutic agents for treating T2D and obesity. However, the route of administration of the GLP-1R agonists is currently by injec...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8a441cd9-ab00-5d78-ada1-93d53edeb3e1
- DOI
- 10.1101/2022.12.21.521368
